John F Crary, MD, PhD Email John Crary
- PROFESSOR | Pathology
- PROFESSOR | Neuroscience
- Anatomic Pathology & Clinical Pathology
- Hospital Affiliation
- The Mount Sinai Hospital
- 212-659-8695 212-659-8695
Dr. Crary is a pathologist who went to Brown University and majored in Neuroscience. This is where he fell in love with brain research, conducting a project looking at NMDA mediated pain processing in the trigeminal system. He received his MD-PhD from SUNY Downstate Medical Center. It is at this time that he developed a strong interest in the neuropathology of Alzheimer's disease, particularly neurofibrillary type degeneration. His thesis research highlighted a unique pattern of neurofibrillary degeneration in the limbic system that is associated with an atypical protein kinase C isoform.
Dr. Crary did his residency and fellowship training in Neuropathology at Columbia University Medical Center and stayed on as an Assistant Professor. There, he conducted seminal work that led to the description of primary age-related tauopathy (PART). In 2014, Dr. Crary established a new neuropathology laboratory at Mount Sinai to continue this work and expand it to other neurodegenerative tauopathies, including chronic traumatic encephalopathy and progressive supranuclear palsy. Dr. Crary has numerous federal and foundation grants to study these diseases. Dr. Crary is a member of the editorial board of Acta Neuropathologica and is a frequent contributor to the Tau Consortium.
Aging, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Axonal Growth and Degeneration, Biomechanics/Bioengineering, Brain, Cancer, Cell Biology, Cytoskeleton, Drosophila, Genetics, Microtubules, Molecular Biology, Neuro-degeneration/protection, Neurobiology, Parkinson's Disease, Pathology, RNA, RNA Splicing & Processing, RNA Transport & Localization
MD, SUNY Downstate Medical Center - College of Medicine
http://www.crarylab.org/home.html Our research focuses on the molecular neuropathology of neurodegenerative diseases. Using an interdisciplinary approach, we are unravelling the molecular changes occurring in diseases with neurofibrillary tangles composed of the tau protein (i.e., tauopathies). This diverse set of brain diseases includes dementias, such as Alzheimer's disease, movement disorders, such as Parkinson's disease and related conditions, and the long-term sequelae of repetitive traumatic brain injury, or chronic traumatic encephalopathy. We are using histological, genetic, biochemical and molecular approaches to pinpoint underlying molecular and cellular triggers of these diseases. Recently, we have begun to deploy powerful artificial intelligence (machine learning)-based approaches, including computer vision, which is revolutionizing our approach to neurodegeneration. Major ongoing NIH-funded projects in the laboratory include: • Clinical, histopathological, biochemical and genetic studies of primary age-related tauopathy (R01NS095252) • Regulation of tau expression in Alzheimer's disease and aging (R01AG054008) • Clinicopathological studies of chronic traumatic encephalopathy (R01AG062348) • Clinicopathological studies of age-related neurodegeneration in HIV/AIDS (RF1AG060961)
Neuropathology Brain Bank and Research CoRE
https://icahn.mssm.edu/research/portal/resources/deans-cores/neuropathology Research conducted using human post-mortem brain tissue remains a critical component of translational brain research programs. To meet the urgent need for this precious resource, the Neuropathology Brain Bank and Research CoRE was launched as part of the Mount Sinai Strategic Plan in July 2018.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Crary did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.